Meropenem/colistin versus meropenem/ampicillin-sulbactam in the treatment of carbapenem-resistant pneumonia

被引：30
|
作者：
Khalili, Hossein [1 ]
Shojaei, Lida [2 ]
Mohammadi, Mostafa [3 ]
Beigmohammadi, Mohammad-Taghi [3 ]
Abdollahi, Alireza [4 ]
Doomanlou, Mahsa [5 ]
机构：
[1] Univ Tehran Med Sci, Fac Pharm, Dept Clin Pharm, Tehran, Iran
[2] Kermanshah Univ Med Sci, Fac Pharm, Dept Clin Pharm, Kermanshah, Iran
[3] Univ Tehran Med Sci, Imam Khomeini Hosp, Fac Med, Dept Intens Care Unit, Tehran, Iran
[4] Univ Tehran Med Sci, Imam Khomeini Hosp, Fac Med, Dept Pathol, Tehran, Iran
[5] Univ Tehran Med Sci, Cent Lab, Imam Hosp Complex, Tehran, Iran
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2018年 / 7卷 / 09期
关键词：
Acinetobacter; ampicillin-sulbactam; colistin; pneumonia; VENTILATOR-ASSOCIATED PNEUMONIA; ACINETOBACTER-BAUMANNII; NOSOCOMIAL PNEUMONIA; AMPICILLIN-SULBACTAM; INTRAVENOUS COLISTIN; RISK-FACTORS; POLYMYXIN-B; MORTALITY; SURVEILLANCE; INFECTIONS;
D O I：
10.2217/cer-2018-0037
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Aim: Efficacy of colistin and ampicillin-sulbactam have not been compared in treatment of ventilator-associated pneumonia due to A. baumannii. Efficacy of colistin and ampicillin-sulbactam in combination with meropenem were compared in treatment of ventilator-associated pneumonia due to carbapenem-resistant A. baumannii. Method: 47 patients with ventilator-associated pneumonia due to carbapenem-resistant A. baumannii were randomized to receive meropenem/colistin or meropenem/ampicillin-sulbactam for 14 days. Clinical and microbiological responses and 28-day mortality were considered as outcomes. Results: Clinical response (75 vs 69.6%; p = 0.75) and microbial eradication (87.50 vs 91.3%; p = 0.59) were comparable between meropenem/colistin and meropenem/ampicillin-sulbactam groups, respectively. Conclusion: In this study, clinical and microbiological response were comparable between the meropenem/colistin and meropenem/ampicillin-sulbactam groups.
引用
收藏
页码：901 / 911
页数：11
相关论文
共 50 条
  • [21] In vitro and in vivo efficacy of cefiderocol plus tigecycline, colistin, or meropenem against carbapenem-resistant Acinetobacter baumannii
    Wentao Ni
    Yifan Wang
    Xinqian Ma
    Yukun He
    Jin Zhao
    Jie Guan
    Yanjun Li
    Zhancheng Gao
    European Journal of Clinical Microbiology & Infectious Diseases, 2022, 41 : 1451 - 1457
  • [22] In vitro and in vivo efficacy of cefiderocol plus tigecycline, colistin, or meropenem against carbapenem-resistant Acinetobacter baumannii
    Ni, Wentao
    Wang, Yifan
    Ma, Xinqian
    He, Yukun
    Zhao, Jin
    Guan, Jie
    Li, Yanjun
    Gao, Zhancheng
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2022, 41 (12) : 1451 - 1457
  • [23] Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections
    Shields, Ryan K.
    McCreary, Erin K.
    Marini, Rachel, V
    Kline, Ellen G.
    Jones, Chelsea E.
    Hao, Binghua
    Chen, Liang
    Kreiswirth, Barry N.
    Doi, Yohei
    Clancy, Cornelius J.
    Nguyen, M. Hong
    CLINICAL INFECTIOUS DISEASES, 2020, 71 (03) : 667 - 671
  • [24] Effect of Colistin, Fosfomycin and Meropenem/ Vaborbactam on Carbapenem-Resistant Enterobacterales in Egypt: A Cross-Sectional Study
    Shrief, Raghdaa
    El-Ashry, Amira H.
    Mahmoud, Rasha
    El-Mahdy, Rasha
    INFECTION AND DRUG RESISTANCE, 2022, 15 : 6203 - 6214
  • [25] CLINICAL EFFICACY OF SITAFLOXACIN-COLISTIN-MEROPENEM AND COLISTIN-MEROPENEM AMONG CARBAPENEM-RESISTANT ACINETOBACTER BAUMANNII HOSPITAL-ACQUIRED PNEUMONIA/VENTILATOR-ASSOCIATED PNEUMONIA PATIENTS: A SINGLE-BLINDED, RANDOMIZED CONTROLLED TRIAL
    Wantanatavatod, M.
    Wongkulab, P.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2023, 130 : S57 - S58
  • [26] In Vitro Synergistic Activity of Sulbactam in Combination with Imipenem, Meropenem and Cefoperazone Against Carbapenem-Resistant Acinetobacter baumannii Isolates
    Dagi, Hatice Turk
    Kus, Halit
    Arslan, Ugur
    Tuncer, Inci
    MIKROBIYOLOJI BULTENI, 2014, 48 (02): : 311 - 315
  • [27] Colistin versus Colistin Combined with Ampicillin-Sulbactam for Multiresistant Acinetobacter baumannii Ventilator-associated Pneumonia Treatment: An Open-label Prospective Study
    Makris, Demosthenes
    Petinaki, Efi
    Tsolaki, Vasssiliki
    Manoulakas, Efstratios
    Mantzarlis, Konstantinos
    Apostolopoulou, Olimpia
    Sfyras, Dimitrios
    Zakynthinos, Epaminondas
    INDIAN JOURNAL OF CRITICAL CARE MEDICINE, 2018, 22 (02) : 67 - 77
  • [28] Cost-utility analysis of ceftazidime-avibactam versus colistin-meropenem in the treatment of infections due to Carbapenem-resistant Klebsiella pneumoniae in Colombia
    Varon-Vega, F. A.
    Lemos, E.
    Castano, Gamboa N.
    Reyes, J. M.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (02) : 235 - 240
  • [29] TREATMENT OF GONORRHEA WITH AMPICILLIN-SULBACTAM
    HANDSFIELD, HH
    SEXUALLY TRANSMITTED DISEASES, 1993, 20 (04) : 237 - 238
  • [30] Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial
    Paul, Mical
    Daikos, George L.
    Durante-Mangoni, Emanuele
    Yahav, Dafna
    Carmeli, Yehuda
    Benattar, Yael Dishon
    Skiada, Anna
    Andini, Roberto
    Eliakim-Raz, Noa
    Nutman, Amir
    Zusman, Oren
    Antoniadou, Anastasia
    Pafundi, Pia Clara
    Adler, Amos
    Dickstein, Yaakov
    Pavleas, Ioannis
    Zampino, Rosa
    Daitch, Vered
    Bitterman, Roni
    Zayyad, Hiba
    Koppel, Fidi
    Levi, Inbar
    Babich, Tanya
    Friberg, Lena E.
    Mouton, Johan W.
    Theuretzbacher, Ursula
    Leibovici, Leonard
    LANCET INFECTIOUS DISEASES, 2018, 18 (04): : 391 - 400
12345